Bill Lundberg

Dr. Bill Lundberg is a medical oncologist with more than 15 years of experience managing and leading biotechnology research and development. Dr. Lundberg is CEO at Merus, a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics. Prior to joining Merus, he served as Chief Scientific Officer at CRISPR Therapeutics, establishing the company in Cambridge, Mass., serving as the first U.S. employee and leading the development of the company’s first clinical trial application. Dr. Lundberg was previously Director and Chief Medical Officer of Taligen Therapeutics and Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, where he oversaw R&D from discovery through early clinical development. Prior to this, Dr. Lundberg held roles of increasing responsibility in drug development and medical affairs at Xanthus (acquired by Antisoma), Wyeth (now Pfizer) and Genzyme. Dr. Lundberg also currently serves as an independent Director of MERUS Therapeutics and a Partner at Cold Spring Partners, LLC. Dr. Lundberg received an MD from Stanford University School of Medicine, an MBA from Isenberg School of Management and a BS from Massachusetts Institute of Technology. He completed postdoctoral training at the Whitehead Institute and trained in internal medicine and oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.